Abstract: A coil component includes a core body, a coil, and a metal terminal. The core body has a mounting surface, an upper surface having a recess, and a side surface. The coil has an embedded part embedded in the core body, and a protruding part protruding from the core body. The metal terminal is electrically connected to the first protruding part of the coil. The first metal terminal has a first plate arranged along the side surface, a second plate connected to an upper end of the first plate and arranged along the upper surface, and a third plate connected to a lower end of the first plate and arranged along the mounting surface. The second plate in the recess has a first arc-shaped part. The recess has a second arc-shaped part. The second arc-shaped part extends along a contour of the first arc-shaped part.

Abstract: A terminal plate member on which a terminal of a coil component is mounted including: an annular frame having an inner peripheral edge; a pair of extension members extending from the inner peripheral edge of the annular frame toward an inner space of the annular frame member in a first direction; and a deformable section provided in the annular frame at proximal end of one of the pair of extension members, the deformable section having a more easily deformable property than other sections of the annular frame when force is applied. The deformable section is provided along at least an entire width in a second direction of the one of the pair of extension members. The second direction is perpendicular to the first direction.

Abstract: A sodium transition metal based cathode material for a rechargeable sodium battery, having a P2 orthorhombic layered bronze crystal structure with space group Cmcm, and having a composition NaxMyMn1-yLiy?AzO2 with 0.60<x<0.95, wherein M consists of either one or more elements of the group consisting of Cu, Zn and Ni; A consisting of either one or more elements of the group consisting of Mg, Ti, Fe, Cr and Co, with 0<y<0.20, 0?z<0.2, 0?y?<0.33, and z+y?>0.

Abstract: A sodium transition metal based cathode material for a rechargeable sodium battery, having a P2 orthorhombic layered bronze crystal structure with space group Cmcm, and having a composition NaxMyMn1-yLiy?AzO2 with 0.60<x<0.95, wherein M consists of either one or more elements of the group consisting of Cu, Zn and Ni; A consisting of either one or more elements of the group consisting of Mg, Ti, Fe, Cr and Co, with 0<y<0.20, 0?z<0.2, 0<y?<0.33, and z+y?>0.

Abstract: A terminal plate member on which a terminal of a coil component is mounted including: an annular frame having an inner peripheral edge; a pair of extension members extending from the inner peripheral edge of the annular frame toward an inner space of the annular frame member in a first direction; and a deformable section provided in the annular frame at proximal end of one of the pair of extension members, the deformable section having a more easily deformable property than other sections of the annular frame when force is applied. The deformable section is provided along at least an entire width in a second direction of the one of the pair of extension members. The second direction is perpendicular to the first direction.

Abstract: A coil component including: a magnetic core which is formed by a magnetic material and which has a top surface, a bottom surface facing the top surface and a side surface continuous approximately perpendicularly to the top surface and the bottom surface; a coil which is buried inside the magnetic core and whose end portion protrudes from the side surface of the magnetic core; a flat-shaped terminal which protrudes from the side surface of the magnetic core, is bent toward the bottom surface of the magnetic core and is connected with the end portion of the coil, wherein there is formed an opening portion at a position corresponding to the place which is bent for the flat-shaped terminal from the side surface to the bottom surface of the magnetic core.

Abstract: Hepatic diseases can be prevented or treated by administering an isoprenylamine derivative represented by the general formula (II) ##STR1## [wherein n represents an integer of 4-12, m represents an integer of 0-3, Ar represents a phenyl group, a furyl group, a thienyl group or a pyridyl group, said group being optionally substituted with one or more of an alkyl group of 1-4 carbon atoms, and alkoxy group of 1-4 carbon atoms, a methylenedioxy group, a hydroxy group or a halogen atom, and R represents a hydrogen atom or an alkyl group of 1-4 carbon atoms] or a pharmacologically acceptable salt thereof at a daily dose of 0.01-500 .mu.g/kg.A lipid emulsion of the compound (II) is particularly useful and can be administered at a remarkably lowered dose as compared with other pharmaceutical preparations.

Abstract: A pharmaceutical oil-in-water type microemulsion having an action of potentiating the activities of anti-cancer agents, said micro-emulsion comprisesfine particles of a vegetable oil or a triglyceride of a medium-chain fatty acid having 8 to 12 carbon atoms containing 0.1 to 10% (w/v) of N-solanesyl-N,N'-bis(3,4-dimethoxybenzyl)ethylenediamine malate of formula (I) below, ##STR1## an aqueous medium, and 0.05 to 25% (w/v) of a physiologically acceptable phospholipid for dispersing said fine particles in said aqueous medium.

Abstract: Disclosed is a rhodanine derivative of formula (I).A rhodanine derivative of formula (I) ##STR1## wherein R.sup.1 is hdyrogen, C.sub.1 -C.sub.8 alkyl, carboxyl(C.sub.1 -C.sub.4)alkyl or (C.sub.1 -C.sub.4)alkoxycarbonyl(C.sub.1 -C.sub.4)alkyl;R.sup.2 is --CH.sub.2 --CH.sub.2 --R.sup.3, CH.dbd.CH.sub.m R.sup.3 (m is 0 or 1), ##STR2## (R is C.sub.1 -C.sub.3 alkyl) or --CH.sub.2n CONHR.sup.4 (n is 0 or 1-4); R.sup.3 is a thienyl or furyl group which may be substituted by C.sub.1 -C.sub.3 alkyl or halogen; a pyrrolyl group which may be substituted by carboxy(C.sub.1 -C.sub.3)alkyl on the nitrogen atom; or a phenyl group which may be substituted by one or more substituents selected from the group consisting of C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy, hydroxyl, halogen, trifluoromethyl, carboxyl, (C.sub.1 -C.sub.3)alkoxycarbonyl, cyano, carboxy(C.sub.1 -C.sub.3)alkoxy, (C.sub.1 -C.sub.6)alkoxycarbonyl(C.sub.1 -C.sub.3)alkoxy, benzyloxycarbonyl(C.sub.1 -C.sub.3)alkoxy, piperidinylcarbonyl(C.sub.1 -C.sub.

Abstract: A pharmaceutical oil-in-water type microemulsion having an action of potentiating the activities of anti-cancer agents, said micro-emulsion comprises fine particles of a vegetable oil or a triglyceride of a medium-chain fatty acid having 8 to 12 carbon atoms containing 0.1 to 10% (w/v) of N-solanesyl-N,N'-bis(3,4-dimethoxybenzyl)ethylenediamine malate of formula (I) below, ##STR1## an aqueous medium, and, 0.05 to 25% (w/v) of a physiologically acceptable phospholipid for dispersing said fine particles in said aqueous medium.

Abstract: Polyprenols and polyprenyl phosphates are of the formula ##STR1## wherein ##STR2## represents a trans-isoprene unit, ##STR3## represents a cis-isoprene unit, ##STR4## represents a dihydroisoprene unit, l is an integer of 2 to 8, m is 0 or an integer of 5 to 18, n is 0 or 1, the sum of l and m is in the range of 8 to 20, and X represents a hydrogen atom or --PO.sub.3 MM' wherein M and M' may be the same or different and each is a hydrogen atom or a monovalent cation or both M and M' together form a divalent cation. They are useful as a medicament for the inhibition of tumor metastasis.

Abstract: Anti-ulcer agents containing isoprenoid derivatives are provided. The isoprenoid derivatives are represented by the formula: ##STR1## wherein: R represents a group of formula ##STR2## In the above formula, R.sub.1, R.sub.2 and R.sub.3 may be the same or different each other and each represents a hydrogen atom, a hydroxy group, a lower alkanoyloxy group, a lower alkyl group or a lower alkoxy group, provided that two or more of them do not represent hydrogen atoms at the same time; R.sub.4 and R.sub.5 may be the same or different each other and each represents a hydrogen atom, a hydroxy group or a lower alkanoyloxy group represents the signal or the double bond between the carbon atoms; m represents 0 or 1; n represents 0 or an integer of from 1 to 9, provided that the sum of m and n is an integer of from 1 to 9.

Abstract: Now is provided a new sustained release drug preparation comprising such an inclusion complex of a medical compound with a hydrophobic cyclodextrin derivative, e.g. ethylated cyclodextrins, which sustains or retards the dissolution and release of the medical compound at a controlled rate from the inclusion complex and hence from the drug preparation containing the inclusion complex, so as to maintain the concentration of the medical compound in blood at an effective level for prolonged time. This drug preparation may further contain a second type of an inclusion complex of the medical compound with a hydrophilic cyclodextrin or hydrophilic cyclodextrin derivative, in mixture with the first type of the inclusion complex of the medical compound with a hydrophobic cyclodextrin derivative, to maintain the controlled release of the medical compound from the drug.

Abstract: New antiviral nonaprenylamine derivatives represented by the following formula ##STR1## wherein R is 4 or 5 atoms selected from the group consisting of C and N so as to complete, with the non-R nitrogen, a 5- or 6-membered heterocyclic ring, and X is selected from the group consisting of H and hydroxy-lower alkyl and non-toxic, pharmaceutically acceptable acid addition salts thereof and a pharmaceutically acceptable carrier.

Abstract: Nonyl prenyl-N heterocyclic compounds are prepared, useful as antivirals.

Abstract: Disclosed herein are saturated and unsaturated aliphatic acids and esters of formula R--Z as defined in the specification which are antiulcer agents.

Abstract: A compound of the formula ##STR1## wherein R.sub.1 is a phenethyl group, R.sub.2 and R.sub.3, taken together with the nitrogen atom to which they are bonded, form an N' hydroxylalkyl substituted piperazine, and (aklylene) is a lower alkylene chain substituted with a hydroxyl group; or an acid addition salt thereof is described.

Abstract: This invention relates to isoprenylamine derivatives and acid addition salts thereof, which compounds are useful for controlling virus infection of vertebrate animals.

Abstract: Four different optical isomers of a new compound, 1-[2'-(o-methoxyphenoxy)-1'-methylethylamino]-3-(4"-isocarbostyriloxy)-2-p ropanol are now provided as new substances. These four optical isomers are now named as (2R, 1'S)-1-[2'-(o-methoxyphenoxy)-1'-methylethylamino]-3-(4"-isocarbostyriloxy )-2-propanol, (2S, 1'S)-1-[2'-(o-methoxyphenoxy)-1'-methylethylamino]-3-(4"-isocarbostyriloxy )-2-propanol, (2S, 1'R)-1-[2'-(o-methoxyphenoxy)-1'-methylethylamino]-3-(4"-isocarbostyriloxy )-2-propanol, and (2R, 1'R)-1-[2'-(o-methoxyphenoxy)-1'-methylethylamino]-3-(4"-isocarbostyriloxy )-2-propanol, respectively. These four optical isomers have different activities for their .beta.-adrenergic-blocking effect and .alpha.-adrenergic-blocking effect and are useful as valuable agents for therapeutic treatment of various cardiovascular diseases, as compared to an optically inactive racemic mixture of said isomer compounds.